Trial Profile
A Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Cefepime/zidebactam Administered as Multiple IV Doses in Healthy Human Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 May 2017
Price :
$35
*
At a glance
- Drugs Zidebactam (Primary) ; Cefepime
- Indications Gram-negative infections
- Focus Adverse reactions; Pharmacokinetics
- 12 May 2017 Results assessing safety, tolerability and pharmacokinetics of Zidebactam and WCK 5222 using patient data from two double blind MAD studies (See CTPs 284673 and 284682), presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
- 12 May 2017 New trial record